India

InCred India Sector rating

Overweight	Neutral	Underweight
Aluminum	Building Materials	Agribusiness
Automobile	Consumer staples	Auto Ancillary
Cement	Information Technology	Aviation
Consumer Electricals	Pharma	Chemicals
Defence	Ports & Logistics	Diagnostics
Financial Services		Metals & Mining
Infrastructure		
Oil and Gas		

India Strategy

Nifty scaling towards a new high

- Macroeconomic indicators continue to improve qoq, beating consensus estimates of economists in recent months on growth as well as cost fronts.
- The Mar 2023 quarter results season recorded the best-ever beat in terms of the number of companies' PAT outperformance in the last two years (Fig. 43).
- Reiterate Overweight rating on Nifty-50 index with a roll-forward target of 20,331, as the EPS momentum takes over from the valuation comfort earlier.

Impressive turnaround in macroeconomic indicators - GDP & CAD

The economic data points indicate an impressive turnaround, as seen in India's GDP growth momentum reversing the slowdown witnessed till Dec 2022, surprising consensus estimates of economists by a huge margin of 100bp to 6.1% in the Mar 2023 quarter and vs. 4.5% in Dec 2022. With the Goods and Services Tax or GST collections scaling a new peak, the current account deficit or CAD is expected to turn positive for the first time in the last six quarters, and the Consumer Price Index or CPI inflation easing mom providing big comfort. The areas of concern are the slow credit growth to industry and import weakness.

Mar 2023 quarter results provide hope


The Mar 2023 quarter results improved sharply in the second half vs. a weak start made by the IT sector at the beginning of the season. The reported EPS rose 2% yoy while the normalized EPS recorded an 8% yoy growth, marginally above consensus estimate. The sectors that witnessed major PAT growth momentum were financial services, automobile, FMCG and infrastructure. However, the major sectors that lagged on the PAT front were metals, chemicals, healthcare and power. Consensus Nifty-50 EPS got downward adjusted only marginally, as the benefits from sectors like financial services and automobile helped.

Easing interest rates to give support to our investment themes

The CPI inflation easing and fresh loan lending rates beginning to decline from their recent peak (Fig. 29) provide hopes of sustaining the revival witnessed in the Mar 2023 quarter. We maintain our investment themes of housing and infrastructure capex, which benefit from this. We have introduced Bharat Electronics in our high-conviction stock ideas list. With the recent rally making the valuations stretched, we have more downgrades like Finolex Cables, NCC, Cera Sanitaryware and Aavas Financiers vs. a few upgrades like HDFC Bank, Astral and Dr. Lal Pathlabs.

Raise Nifty-50 target to 20,331;remain Overweight

With the comfort level improving in respect of economic growth recovery supporting the Nifty-50 Bloomberg consensus EPS outlook, we roll forward our target to 1-year forward EPS methodology, from Mar 2024F earlier. To incorporate the uncertainty that lies ahead, we have reduced our bull-case probability to 30%, yielding a blended Nifty-50 target of 20,331 (Fig. 51). The Nifty Midcap Index, scaling a new high as a proportion of market capitalization, may demand consolidation (Fig. 50).



Analyst(s)



Pramod AMTHE T (91) 22 4161 1541 E pramod.amthe@incredcapital.com India Strategy Note ⊤ June 07, 2023


Figure 2: Our high-conviction stock ideas


Company	BLOOMBERG TICKER	Reco.	Market Capital (Rsbn)	Market Capital (US\$bn)	Price	Target U Price	lp/down (%)		EPS	6		3yr EPS CAGR (FY22-		P/E (x)		P/BV	(x)	EV/EBITDA (x)	Dividend Yield (%)	ROE %
			、 ,					FY22A	FY23A	FY24F	FY25F	FY25F) —	FY23	FY24F	FY25F	FY23	FY24F	FY23	FY23	FY23
Ashok Leyland	AL IN	ADD	446	6.1	152	181	19%	0.3	4.4	6.8	8.8	217%	32.3	22.4	17.2	5.3	4.8	13.9	171%	16.5
BCL Industries	BCLIL IN	ADD	11	0.2	475	790	66%	35.1	26.1	65.9	80.7	32%	18.2	7.2	5.9	4.0	2.6	13.6	16%	25.5
Bharat Electronics	BHE IN	ADD	863	11.9	118	140	19%	3.2	4.1	4.7	5.7	21%	28.7	25.3	20.8	6.4	5.6	19.3	152%	23.5
Bharat Forge	BHFC IN	ADD	376	5.2	808	918	14%	22.6	10.5	19.7	25.6	4%	93.3	41.0	31.6	5.6	4.2	23.2	99%	8.3
Camlin Fine Sciences	CFIN IN	ADD	28	0.4	169	300	78%	4.2	6.2	15.1	21.8	72%	27.1	11.2	7.8	2.8	2.1	14.4	37%	11.5
Container Corp. of India	CCRI IN	ADD	410	5.6	673	940	40%	19.1	20.2	25.9	42.1	30%	33.4	26.0	16.0	3.5	3.2	19.5	90%	11.0
Dalmia Bharat	DALBHARA IN	ADD	406	5.6	2,167	2,250	4%	43.3	64.4	59.8	72.9	19%	30.6	36.2	29.7	2.6	2.4	17.8	23%	7.5
Globus Spirits	GBSL IN	ADD	34	0.5	1,184	3,014	155%	65.0	46.0	120.6	140.5	29%	25.7	9.8	8.4	3.8	2.8	13.9	23%	15.9
Home First Finance Company	HOMEFIRS IN	ADD	70	1.0	796	950	19%	21.2	26.1	31.6	38.0	21%	30.6	25.2	21.0	3.8	3.3	NA	0%	13.5
InterGlobe Aviation	INDIGO IN	REDUCE	933	12.8	2,420	1,600	-34%	-141.9	6.5	-16.0	-9.3	-60%	-34.4	-151.4	-260.9	-10.7	-10.0	16.6	0%	-3.4
Kajaria Ceramics	KJC IN	ADD	200	2.8	1,255	1,376	10%	23.7	22.0	27.6	36.2	15%	58.0	45.5	34.7	8.6	7.8	33.6	72%	21.1
KEC International	KECI IN	ADD	135	1.9	527	571	8%	14.3	6.8	25.1	38.0	38%	76.9	21.0	13.8	3.6	3.2	19.8	76%	4.8
Mahindra & Mahindra Finance	MMFS IN	ADD	360	5.0	292	350	20%	8.0	16.1	19.2	23.2	43%	18.1	15.2	12.6	2.1	1.9	NA	206%	12.1
Maruti Suzuki	MSIL IN	ADD	2,932	40.4	9,708	11,061	14%	128.1	266.5	373.4	466.3	54%	36.4	26.0	20.8	4.9	4.3	22.8	93%	14.1
Reliance Industries	RIL IN	ADD	16,902	232.8	2,498	3,369	35%	100.7	162.2	178.7	NA	NA	15.4	14.0	NA	1.8	1.7	8.7	32%	12.7
Spandana Sphoorty Financial	SPANDANA IN	ADD	50	0.7	699	850	22%	10.1	1.7	65.6	90.3	107%	399.8	10.7	7.7	1.6	1.3	NA	0%	0.4
Sun Pharmaceutical Industries	SUNP IN	ADD	2,434	33.5	1,015	1,187	17%	32.4	32.8	36.2	42.2	9%	31.0	28.0	24.0	4.6	4.1	21.0	99%	15.5
Tata Motors	TTMT IN	REDUCE	2,036	28.0	568	401	-29%	-22.8	-9.3	20.2	39.4	-220%	-64.6	28.2	14.4	4.8	4.2	8.3	35%	-7.9
Tata Steel	TATA IN	REDUCE	1,363	18.8	112	70	-37%	34.2	10.3	5.3	NA	NA	10.8	21.2	NA	1.1	1.1	6.4	18%	10.6
Titan Company	TTAN IN	ADD	2,581	35.5	2,907	3,150	8%	24.9	36.5	44.1	53.6	29%	79.6	66.0	54.3	22.3	18.1	52.8	38%	31.1
UltraTech Cement	UTCEM IN	ADD	2,355	32.4	8,158	8,530	5%	248.9	175.4	239.2	290.6	5%	46.5	34.1	28.1	4.3	3.9	22.5	56%	9.7
Zydus Lifesciences	ZYDUSLIF IN	ADD	521	7.2	515	593	15%	23.4	22.9	29.0	34.4	14%	22.5	17.7	15.0	2.9	2.6	14.5	116%	13.3
																SOU	RCE: INCR	ED RESEARCH	I, COMPANY F	REPORTS

Performance scaling towards a new high

Strong economic recovery in Mar 2023 quarter is impressive ➤


Domestic economic activity showed a strong recovery in the Mar 2023 quarter, after a muted performance in Sep and Dec 2022 quarters on the gross domestic product or GDP growth front. The sustained growth momentum in GST collections, E-way bills, Purchasing Managers' Index or PMI and consumer sentiment provide comfort. Easing inflation also provides comfort in respect of interest rates peaking, raising hopes of a recovery in private consumption. However, the areas of concern are a slow credit growth to industry, weakness in imports and El Nino's adverse impact on India's rural economy. While the fiscal consolidation path followed by the Government of India's recent budget is impressive, the recent loss of the ruling Bharatiya Janata Party in Karnataka assembly elections may raise government spending in rural areas ahead of the general elections scheduled in May 2024.







InCred Equities

India Strategy Note ∣ June 07, 2023









4

InCred Equities

India Strategy Note ∣ June 07, 2023








Consumer sentiment remains strong >


The consumer sentiment, as per the Reserve Bank of India or RBI data continued to improve in Mar 2023, rising by 220bp to 87%, on account of improved perception on the general economic situation, employment, and household income. With an uptick in the current perception, the sentiment on employment is nearing the level seen around mid-2019; consumers are also optimistic about the employment outlook as more than half of the respondents in the RBI's household survey expecting the employment scenario to improve over the next one year.

The Index of Consumer Sentiment (ICS) tracked by the Centre for Monitoring Indian Economy or CMIE improved marginally in May 2023. The ICS inched up by 90bp during the month. This was the fifth consecutive month of an improvement in consumer sentiment in India. During these five months, consumer sentiment scaled up cumulatively by 17.4 percentage points. In the coming months of 2023F, the ICS could face challenges from the monsoon which is already quite delayed, and precipitation is expected to be below the long-period average (as per the India Meteorological Department or IMD). Assembly elections in large states of the country towards the end of this year could also cause some volatility in consumer sentiment as political parties are inclined to give/promise freebies. Interestingly, while the uncertainty regarding the prospects on the agricultural front has increased in the past two months, rural consumer sentiment fared quite well. Rural consumer sentiment increased by 1.2 per cent in May 2023 while the urban consumer sentiment increased by only 0.5 per cent.










GDP growth outperformance in Mar 2023 quarter is impressive **>**


India's Mar 2023 quarter GDP growth surprised positively at 6.1% yoy vs. consensus estimate of 5%. Sequentially, in seasonally adjusted annualized terms, the growth in the economy rose to 10%, helped by most segments on the supply side. The main reason for the better-than-expected performance has been a significant traction in fixed investments and exports on the demand side and the growth in construction and trade, hotel & hospitality sectors on the supply side. The sharp decline in imports also helped. Private consumption remains the main source of disappointment.

With inflation beginning to ease, we expect private final consumption expenditure growth to provide support to GDP growth. In the upcoming monetary policy, the RBI is expected to raise GDP growth outlook, as seen from a few economists already raising their estimates by 50+bp to near 6% for FY24F. However, the full benefits of Bloomberg consensus estimates are yet to flow through.



InCred Equities


India Strategy Note | June 07, 2023




Positive CAD hopes in Mar 2023 quarter ➤


India's external sector was buffeted by deteriorating global macroeconomic conditions following the ongoing Russia-Ukraine war that impacted trade and capital flows adversely. Even as domestic economic recovery kept import demand high, the slowdown in global demand weighed on India's exports. These, together with the adverse net terms of trade shock associated with record-high global commodity prices, expanded India's merchandise trade deficit during the year. Notwithstanding a robust growth in services exports and higher remittance receipts, the widening of merchandise trade deficit and higher outgo on the primary income account led the current account deficit (CAD) to widen during the year, which peaked in 2QFY23. While net capital inflows dominated by foreign direct investment (FDI) and banking capital supported financing of CAD, significant foreign portfolio outflows during the year necessitated the drawdown of foreign exchange reserves. Valuation losses, primarily due to a large appreciation of the US dollar (USD) against non-USD reserve currencies, constituted a major part of the depletion of foreign exchange reserves during the year. Nonetheless, the external sector stood resilient against global spillovers, with India's vulnerability indicators faring better than its peer emerging market economies.


Record-high merchandise exports were observed in FY23 at US\$449.9bn, a growth of 6.5% yoy. The CMIE projects merchandise exports to be around US\$ 440bn in FY24F due to the global slowdown. India is expected to post a current account surplus in the quarter ended Mar 2023, driven by declining commodity prices, robust services exports and rising remittances from overseas Indians. If realized, this surplus would be the first in six quarters. India Ratings and Research (Ind-Ra) estimates the current account surplus at US\$6bn or 0.7 per cent of GDP for Jan-Mar 2023.











10





Figure 23: Bloomberg consensus estimates on Gol's fiscal deficit (as a % of GDP) may be at risk post Karnataka assembly election loss for the BJP





RBI's accomodative stance to continue ▶

Economists' survey indicates that RBI will maintain the repo rate at its 8 Jun 2023 monetary policy meeting. Their expectation is driven by the recent decline in Consumer Price Index or CPI-based inflation. Retail inflation eased to an 18-month low of 4.7 per cent in Apr 2023, well within the RBI's target range of 2 to 6 per cent. The consensus among economists is that the central bank will maintain its current stance of withdrawing accommodation. A few economists expect a downward revision of the inflation forecast and an upward revision in the RBI's growth forecast for FY24F.


InCred Equities


India Strategy Note | June 07, 2023





SOURCE: BLOOMBERG, INCRED RESEARCH






Investment themes

We continue to like housing and infrastructure capex investment themes as a top-down approach, with management commentaries during the recent results season supporting them. Except for a few stretched valuation-led downgrades, we maintain our stock picks. The gross margin expansion of our inflation-proof theme stocks is more visible, as input cost inflation started easing in the Mar 2023 quarter.

Sustained housing demand uptrend is impressive >

The residential real estate sector in India is witnessing a remarkable transformation, driven by evolving consumer preferences, changing lifestyles, and demographic shifts. A record-breaking number of 247,000 new residential units were launched in 2022 (+81% yoy), marking the second-highest number of launches in a decade, falling behind only the peak of 281,000 units in 2010. As the country's economy continues to recover and urbanization remains a vital driver, the real estate sector's growth potential will remain robust, offering immense opportunities. The home loan rates peaking at 9.02% and their gradual decline expected in the rest of FY24F, in our view, should help sustain the demand growth momentum.





India	
Strategy Note	June 07, 2023


Figure 33: Ben	eficiaries of r	evival	in ho	using d	emand											
Company Name	Bloomberg Ticker	Reco.	Price	Target Price	Market Capital	pital Capital EPS (Rs) P/E		P/E (x)	P	/BV (x)	EV/EBITDA (x)	Dividend Yield (%)	Upside/ Downside	ROE (%)		
	TICKEI		Rs	Rs	(Rs bn)	(US\$ bn)	FY23	FY24F	FY23	FY24F	FY23	FY24F	FY23	FY23	(%)	FY23
Astral	ASTRA IN	ADD	1,910	1,978	583	7.1	17.7	21.6	108.6	88.5	18.9	16.1	62.9	0.1	4%	25.0
Century Plyboards	CPBI IN	ADD	573	734	145	1.8	16.5	19.0	34.7	30.1	6.7	5.5	23.7	0.2	28%	28.5
Crompton	CROMPTON IN	ADD	278	320	202	2.5	7.0	8.8	40.0	31.6	6.6	6.0	23.8	1.1	15%	22.6
Kajaria Ceramics	KJC IN	ADD	1,243	1,376	225	2.7	22.0	27.6	57.4	45.0	8.5	7.7	33.2	0.7	11%	21.1
UltraTech Cement	UTCEM IN	ADD	8,110	8,530	2,660	32.2	175.4	239.2	46.2	33.9	4.3	3.9	22.3	0.6	5%	9.7
V-Guard Industries	VGRD IN	ADD	253	290	125	1.5	4.4	6.3	58.0	40.4	6.8	6.1	35.4	0.5	15%	17.0
Voltas	VOLT IN	ADD	803	942	302	3.7	11.4	20.5	70.3	39.3	4.9	4.4	41.4	0.7	17%	6.9
									SOUP	RCE: INC	RED RI	ESEARCI	H ESTIMATES, E	BLOOMBERG,	COMPANY RE	PORTS
														NOTE: PRIC	ES AS ON 7 JI	JN 2023


Strong order inflow from infrastructure capex >

Aggregate order inflow in FY23 was robust for capital goods companies under our coverage at +36% yoy, led by Siemens (+600%) and KEC International (+121%). New investments announced by the manufacturing sector in FY23 grew 23% yoy. We expect a new trend of private sector spending led by energy transition including renewables, electric vehicles, battery technology, and hydrogen. We expect the order inflow of our coverage companies to clock a 14% CAGR over FY24F-25F.

The Gol's budget allocation to the infrastructure sector is expected to rise by 28% yoy to Rs8.9tr in FY24F, with the thrust on railways and roads. An average order book or OB-to-sales ratio at a healthy ~2.8x for construction & infrastructure companies in our coverage augurs well for sales growth in FY24F-25F.

Private sector capex recovery may be gradual to flow through because of debt challenges faced by a few large groups like the Adani Group and the recent credit rating challenges witnessed in a rising interest rate environment.








Figure 37: Benef	ficiaries of s	pendir	n <mark>g o</mark> n in	frastru	cture											
Company Name	Bloomberg Ticker	Reco.	Price Rs	Target Price	Market Capital	Market Capital	EF	PS (Rs)		P/E (x)	Р	/BV (x)	EV/EBITDA (x)		Upside/ Downside	ROE (%)
	TICKEI		КS	Rs	(Rs bn)	(US\$ bn)	FY23	FY24F	FY23	FY24F	FY23	FY24F	FY23	FY23	(%)	FY23
Adani Ports	ADSEZ IN	ADD	745	823	1,830	22.2	34.1	41.0	21.9	18.2	3.5	3.0	15.4	0.6	0.1	22.1
Container Corp.	CCRI IN	ADD	670	940	464	5.6	20.2	25.9	33.2	25.9	3.5	3.2	19.4	0.9	0.4	11.0
KEC International	KECI IN	ADD	533	571	156	1.9	6.8	25.1	77.8	21.2	3.6	3.2	19.9	0.8	0.1	4.8
Larsen & Toubro	LT IN	ADD	2,278	2,515	3,639	44.1	73.6	93.8	31.0	24.3	3.6	3.2	21.0	0.9	0.1	12.0
UltraTech Cement	UTCEM IN	ADD	8,110	8,530	2,660	32.2	175.4	239.2	46.2	33.9	4.3	3.9	22.3	0.6	0.1	9.7
										SO	JRCE:	INCRED	RESEARCH E	STIMATES,	COMPANY R	EPORTS

NOTE: PRICES AS ON 7 JUN 2023

Inflation-proof stocks show fast gross margin expansion as inflation eases ➤


While corporates have been eager to raise product prices and pass on the inflation in input cost to their consumers, very few have a long-term track record of resilient gross/EBITDA margins. Our stock picks on this theme not only limited the inflation impact on gross margin but with the inflation easing in 4QFY23, the bounce-back in their gross margin was impressive.

Companies operating in sectors like mining and metals, oil & gas, utilities, and pharmaceuticals stand out with a high gross margin.

InCred Equities

India	
Strategy Note	June 07, 2023

•				_	a high-i									Dividend	llmaide/	DOF
Company Name	Bloomberg Ticker	Reco.	Price Rs	Target Price	Market Cap	Market Cap		S (Rs)	I	P/E (x)	P	/BV (x)	EV/EBITDA (x)		Upside/ Downside	ROE (%)
	ncker		RS	Rs	(Rs bn)	(US\$ bn)	FY23	FY24F	FY23	FY24F	FY23	FY24F	FY23	FY23	(%)	FY23
Bharat Forge	BHFC IN	ADD	803	918	425	5.1	10.5	19.7	92.6	40.7	5.6	4.1	23.0	1.0	0.1	8.3
Colgate-Palmolive India	CLGT IN	HOLD	1,620	1,645	501	6.1	38.9	43.8	41.6	37.0	25.7	24.8	27.9	2.4	0.0	61.3
Hindustan Unilever	HUVR IN	ADD	2,691	2,720	7,186	87.1	42.4	47.4	63.8	56.8	12.6	12.0	45.8	1.3	0.0	20.2




4QFY23 EBITDA margin recovery provides comfort


Consensus EPS miss trend stabilizes >

The Mar 2023 quarter EPS posted a muted 2% yoy growth, after being in the negative zone for previous two quarters. The sharp deceleration in EPS momentum seems to have turned around in the Mar 2023 quarter, as gross margin continued to improve qoq. Adjusted for one-offs, Nifty-50 companies' profits rose by 7.5% yoy in the Mar 2023 quarter, driven by financial services, automobile, FMCG and infrastructure sectors. However, the major laggards on the PAT front were metals, chemicals, healthcare and power sectors.


In terms of PAT beat distribution, nearly 46% of Nifty-50 companies extended their beat, the highest since the Dec 2020 quarter. Considering that a smaller proportion of companies extended their sales beat during the quarter, the PAT beat seems to have come from the EBITDA margin improvement. The EBITDA margin of non-financial services sector companies improved by 40bp qoq to 15.4%.


The reduction in FY23-25F Bloomberg EPS estimates continued in the recent results season as well, to the extent of 0.5-1%, as downgrades in the IT sector were overcome by upgrades in automobile and financial services sectors.






India Strategy Note | June 07, 2023








InCred Equities

India Strategy Note | June 07, 2023




Nifty valuation and outlook

Index valuation easing to below mean level provides comfort **>**

The Nifty-50 Index took support at -1SD of the 10-year mean level in recent monthly lows to bounce back marginally above this valuation zone but is still below the mean level. The tailwinds from improving domestic macroeconomic factors from the lows of Dec 2022 and stability in the global macroeconomic environment provides comfort. The Nifty Mid-cap Index scaling a new high already and stocks in the basket of Rs251-500bn market capitalization range scaling a new peak in the proportion to form 9.6% of total India stock market capitalization are areas of concern.


We expect high volatility in the index to continue, considering the wide swing in macro variables globally influencing the estimates/sentiment. We continue to maintain our base-case, bull-case, and bear-case Nifty P/E targets at 20x,18x and 16x, respectively. But improved tailwinds from macroeconomic factors and visibility on corporate earnings led us to roll forward our target EPS to the one-year forward methodology, from Mar 2024F earlier. The roll forward to a future period, where the uncertainty can be higher, led us to have a lower probability of a bull-case scenario at 30% now vs. 40% earlier, while we have raised the bear-case scenario probability to 20% from 10% earlier. With the earnings roll-forward benefit being stronger, we have lifted our blended Nifty-50 index target to 20,331, an upside of 9% from the current levels.



InCred Equities

India Strategy Note | June 07, 2023





SOURCE: BLOOMBERG, INCRED RESEARCH


Figure 50: Market cap distribution of stocks in top-500 stocks indicate excess fizz in the mid-cap rally, as stocks in the basket of Rs251-500bn market-cap list scale a new-high proportion at 9.6% of total market cap




Figure 51: Weighing Nift	y index against ecor	nomic scenarios	
	Bull Case	Base Case	Bear Case
Economic variables for FY24F	GDP growth >7%, Brent crude oil <us\$105 bbl,="" inflation<br=""><5%, repo rate hike <75bp, above-normal monsoon</us\$105>	GDP growth >6%, Brent crude oil <us\$120 bbl,<br="">inflation <6%, repo rate hike <100bp, normal monsoon</us\$120>	GDP growth <6%, Brent crude oil >US\$125/bbl, inflation >7%, repo rate hike >100bp, below- normal monsoon
Probability of event	30%	50%	20%
EPS (FY24F)	1,117	1,117	1,117
Target P/E (x)	20.0	18.0	16.0
Target index	22,342	20,107	17,873
Nifty-50 now	18,600	18,600	18,600
Up/ downside	20.1%	8.1%	-3.9%
Blended Index target		20,331	
		NOTE: FY24F EPS IS	S OF BLOOMBERG CONSENSUS
		SOURCE: BLO	OMBERG, INCRED RESEARCH

InCred Equities

India Strategy Note ∣ June 07, 2023





Sector-wise rating and stock ideas >

The Nifty-50 index witnessed a sharp rise in recent months aided by acceleration in foreign institutional investor or FII inflow in May 2023, good Mar 2023 quarter corporate results and improving macroeconomic data points. The key sectors driving the outperformance are realty, automobile and FMCG in the YTDCY23 period.

Last few weeks, the companies in our coverage universe witnessed more downgrades driven by valuation challenges like Finolex Cables, NCC, Cera Sanitaryware, Aavas Financiers and PNC Infratech vs. a few upgrades like HDFC Bank, Astral, and Dr.Lal Pathlabs.





Figure 57: Our sector-wise ratings											
Overweight	Neutral	Underweight									
Aluminium	Building Materials	Agribusiness									
Automobile	Consumer staples	Auto Ancillary									
Cement	Information Technology	Aviation									
Consumer Electricals	Pharma	Chemicals									
Defence	Ports & Logistics	Diagnostics									
Financial Services		Metals & Mining									
Infrastructure											
Oil and Gas											
		SOURCE: INCRED RESEARCH									



India	
Strategy Note	June 07, 2023

Figure 59: Non-consensus stocks with a REDUCE rating in our coverage universe (removed GAIL as its rating upgraded from REDUCE to HOLD)

Company Name	Bloomberg	Reco.	Price		Market Capital	Market Capital	EI	PS (Rs)		P/E (x)	P	/BV (x)	EV/EBITDA		Upside/ Downside	ROE (%)
	Ticker		Rs			(US\$ bn)	FY23	FY24F	FY23	FY24F	FY23	FY24F	FY23	FY23	(%)	
Apollo Tyres	APTY IN	REDUCE	392	256	283	3	14.3	17.5	27.3	22.3	2.0	1.9	9.3	1.5	-0.3	7.6
Ami Organics	AMIORG IN	REDUCE	1,195	714	49	1	21.3	24.7	56.2	48.3	7.6	6.8	37.1	-	-0.4	14.2
Avanti Feeds	AVNT IN	REDUCE	389	353	60	1	15.5	22.1	25.7	17.6	2.6	2.3	17.0	0.8	-0.1	10.8
Balrampur Chini Mills	BRCM IN	REDUCE	392	229	90	1	13.4	24.9	29.4	15.7	2.7	2.3	17.6	0.2	-0.4	13.7
Clean Science and Technology	CLEAN IN	REDUCE	1,407	660	170	2	26.8	29.4	52.6	47.9	15.6	12.9	39.4	-	-0.5	33.0
Delhivery	DELHIVER IN	REDUCE	355	263	294	4	(17.6)	(11.5)	(19.9)	(30.7)	2.9	3.3	(26.4)	-	-0.3	(16.4)
Dhanuka Agritech	DAGRI IN	REDUCE	778	704	40	0.5	45.6	48.2	17.0	16.1	3.3	2.9	(0.6)	1.2	-0.1	21.0
Eicher Motors	EIM IN	REDUCE	3,705	3,284	1,152	14.0	106.6	122.2	34.8	30.3	7.7	6.7	25.6	1.0	-0.1	22.6
Gujarat Gas	GUJGA IN	REDUCE	479	410	375	4.5	15.7	17.8	30.5	27.0	5.1	4.4	17.3	0.4	-0.1	18.2
Hero MotoCorp	HMCL IN	REDUCE	2,905	2,238	660	8.0	137.7	183.0	21.1	15.9	3.5	3.3	12.1	3.4	-0.2	17.0
InterGlobe Aviation	INDIGO IN	REDUCE	2,410	1,600	1,056	12.8	6.5	(16.0)	(34.2)	(150.8)	(10.6)	(9.9)	16.5	-	-0.3	(3.4)
Polycab India	POLYCAB IN	REDUCE	3,595	3,126	612	7	80.2	86.8	44.8	41.4	8.1	7.1	28.1	0.6	-0.1	19.7
SRF	SRF IN	REDUCE	2,533	1,540	853	10	60.9	53.7	41.6	47.1	7.4	6.4	24.5	0.2	-0.4	19.2
Tata Motors	TTMT IN	REDUCE	556	401	2,266	27.5	(9.3)	20.2	(63.3)	27.6	4.7	4.1	8.2	0.4	-0.3	(7.9)
Tata Steel	TATA IN	REDUCE	109	70	1,514	18.3	10.3	5.3	10.5	20.7	1.1	1.0	6.3	1.8	-0.4	10.6
UPL	UPLL IN	REDUCE	694	754	592	7.2	53.6	61.9	14.7	12.5	1.9	1.7	7.6	1.8	0.1	18.4
VRL Logistics	VRLL IN	REDUCE	698	426	69	1	19.7	11.3	19.7	61.9	7.0	6.6	14.7	0.7	-0.4	16.4
								SO	URCE:	INCRED I	RESEA	RCH EST	TIMATES, BLO	OMBERG, C	OMPANY RE	PORTS

NOTE: PRICES AS ON 7 JUN 2023

Company Name	Bloomberg Ticker	Reco.	Price		Market Capital	Market Capital	EF	PS (Rs)		P/E (x)	P	/BV (x)	EV/EBITDA (x)	Dividend Yield (%)	Upside/ Downside	
	TICKEI		Rs	Rs	(Rs bn)	(US\$ bn)	FY23	FY24F	FY23	FY24F	FY23	FY24F	FY23	FY23	(%)	FY2
Apex Frozen Foods	APEX IN	ADD	214	385	8	0.1	14.4	25.7	14.9	8.3	1.3	1.1	12.5	0.7	0.8	12.2
Balkrishna Industries	BIL IN	REDUCE	2,297	1,730	505	6.1	55.9	69.3	41.1	33.2	5.9	5.2	24.5	0.7	-0.2	14.9
Coastal Corp	CTW IN	ADD	202	990	3	0.0	14.5	55.3	13.9	3.6	1.0	0.8	12.3	1.3	3.9	10.7
Crompton	CROMPTON IN	ADD	278	320	202	2.5	7.0	8.8	40.0	31.6	6.6	6.0	23.8	1.1	0.2	22.6
Cyient	CYL IN	ADD	1,339	1,204	168	2.0	50.0	65.5	28.6	20.4	4.2	3.9	14.7	1.9	-0.1	22.1
Endurance Technologies	ENDU IN	ADD	1,483	1,647	237	2.9	34.5	50.3	43.5	29.5	4.7	4.2	20.3	0.5	0.1	11.7
Globus Spirits	GBSL IN	ADD	1,119	3,014	37	0.4	46.0	120.6	24.3	9.3	3.6	2.6	13.2	0.2	1.7	15.9
Gujarat Pipavav Port	GPPV IN	ADD	111	148	61	0.7	6.7	8.3	16.5	13.4	2.6	2.4	8.2	5.0	0.3	15.8
Home First Finance company	HOMEFIRS IN	ADD	780	950	78	0.9	26.1	31.6	29.9	24.7	3.8	3.3	NA	-	0.2	13.5
KEC International	KECI IN	ADD	533	571	156	1.9	6.8	25.1	77.8	21.2	3.6	3.2	19.9	0.8	0.1	4.8
Meghmani Finechem	MEGHFL IN	ADD	1,097	2,151	52	0.6	86.6	107.5	12.7	10.2	3.5	2.6	9.1	-	1.0	39.7
Mphasis	MPHL IN	ADD	1,914	1,981	410	5.0	86.2	93.5	22.2	20.5	4.6	4.2	14.3	2.6	0.0	22.0
Persistent Systems	PSYS IN	ADD	4,981	5,100	435	5.3	120.5	155.0	41.3	32.1	9.6	8.0	24.5	1.0	0.0	33.8
PI Industries	PI IN	REDUCE	3,587	2,417	618	7.5	82.2	85.2	43.7	42.1	7.4	6.4	32.3	0.1	-0.3	18.6
Supreme Industries	SI IN	ADD	2,825	3,247	408	4.9	68.1	80.0	41.5	35.3	8.2	7.1	29.3	0.9	0.1	27.0
Zydus Lifesciences	ZYDUSLIF IN	ADD	515	593	593	7.2	22.9	29.0	22.5	17.7	2.9	2.6	14.5	1.2	0.2	13.3

NOTE: PRICES AS ON 7 JUN 2023

Automobile sector

- A good results season for our coverage universe stocks, as 81% of them beat on the EBITDA front. The big beat was in commercial vehicle or CV, twowheeler or 2W OEMs and tyre makers. Battery makers and a few companies with international exposure disappointed in the auto ancillary segment.
- Among original equipment manufacturers or OEMs, gross margin qoq improvement was across companies except Maruti Suzuki. A major upmove was in case of 2W makers. The auto component segment saw a qoq upmove, barring Bosch and Exide Industries.
- We raise our EBITDA estimates across OEMs, barring Escorts and TVS Motor. We have raised CV makers' EBITDA estimates sharply. In the auto ancillary segment, we have cut EPS estimates for Balkrishna Industries and Bharat Forge because of slow global market recovery.
- We reiterate Overweight rating on the auto sector as the NSE auto P/E valuation trades below the 10-year mean level and volume surprises flow in. With benign volume growth expectations due to a high base and a peak interest rate scenario, we have kept expectations at check. Subject to good rainfall distribution and interest rate cut prospects, we feel there is scope for volume surprise in 2HFY24F. New model launches, and pricing power benefit leads to our ADD rating on Maruti Suzuki, Ashok Leyland, Bajaj Auto and Mahindra & Mahindra. While 2W demand looks promising and the electric vehicle or EV risk eases from demand incentive cut, we prefer Bajaj Auto as our top pick, followed by our REDUCE rating on Hero MotoCorp, Eicher Motors and TVS Motor.

 We reiterate REDUCE rating on Tata Motors and TVS Motor as global operation challenges overrule domestic recovery benefit at current rich valuations. In the auto ancillary segment, we have an ADD rating on Bharat Forge, Endurance Technologies and Exide Industries, and a REDUCE rating on Bosch and Balkrishna Industries. We have a HOLD rating on Apollo Tyres.

Building material and consumer electrical sectors

- Durables:
 - 0 B2C sales continued with a weak demand trend (real estate inventory time lag, inflation, exhaustion of replacement demand post Covid-19 pandemic) while B2B sales supported revenue growth. Summer product sales were negatively impacted due to unseasonal rains in North/West India in Mar 2023. This continued in May/Jun 2023. Secondary sales of room ACs, fans, coolers and related electronic products have been suboptimal throughout Mar-May 2023, and channel inventory higher than the long-term average. Cable and wire companies continued to report a higher revenue growth vs. consumer durables and small domestic appliance companies. Havells (C&W division), Polycab, KEI Industries and Finolex Cables reported higher revenue growth vs. CG Consumer, Orient Electric and V-Guard. As regards the margins, the impact of old high-cost raw materials is fading and most durable companies reported an improvement in gross/EBITDA margins gog. Advertising and marketing expenses are trending back to pre-Covid levels.
 - Outlook: There is a lot of hope on summer sales recovery in 1QFY24F, given expectations of an elongated summer season in India. The ECD segment's margins are expected to fully recover to pre-Covid levels. C&W companies are expected to report good sales volume growth, but revenue growth could be lower due to falling realization because of declining copper prices.
 - Preferred stocks: Continue to like Havells, CG Consumer and KEI Industries among the companies in our consumer durables companies' universe. We have downgraded Finolex Cables to a REDUCE rating.
- Building materials:
 - Steel pipes, plastic pipes, sanitaryware, faucets, plywood and MDF saw good sales volume in 4Q. Tiles and laminates saw demand compression among our coverage companies. Input prices have corrected from their peaks, except timber that continues to impact gross margin for wood panel companies. Most companies have created new capacities that are underutilized. Management expects significant demand pick-up across products, given the robust pipeline of private and public sector construction projects.
 - Outlook: Building material is witnessing a much better demand trend vs. other consumer discretionary items. We expect meaningful sales volume growth across products over FY23-25F.
 - **Preferred stocks**: Continue to like APL Apollo and Kajaria Ceramics. We have upgraded Astral to an ADD rating, given the favourable risk-reward ratio at current valuations.

Banking/NBFC sector

4QFY23 results review: Banks/NBFCs under our coverage reported strong credit growth during the quarter (State Bank of India, HDFC Bank, and Cholamandalam remain outliers). During the quarter, corporate growth was also supportive in addition to retail and SME segments. Margin expansion for banks continued, but banks indicated peak margins in 4Q, as deposit repricing will now impact the cost of funds & margins. While NBFCs saw margin pressure but now, due to increased rates on fixed-rate loans, they witness better margins. The asset quality trend continued to improve, with lower slippage across segments resulting in lower provisioning.

- Eye on consumption and interest rates: Most banks/NBFCs, in their postresults commentary, remained optimistic on future credit demand and indicated strong credit demand in FY24F. We believe credit demand will remain strong for private sector banks and NBFCs.
- Liability augmentation to determine the future course of action: Banks have indicated repricing of deposits which will assist in liability augmentation in the coming quarters, as we witnessed overall deposit growth remaining relatively weak (SBI, Axis Bank & IndusInd Bank remain at the lower end) compared to the expansion in credit. The loan-deposit ratio for most banks already remains stretched (ICICI Bank, Axis Bank & HDFC Bank at the upper end). However, State Bank of India or SBI with a low loan-deposit ratio, is well positioned. Raising liabilities (deposits as well as borrowings) continue to remain an expensive affair, especially for NBFCs as well as small- and mid-size banks compared to large banks. Banks like HDFC Bank & ICICI Bank have indicated strong branch expansion plans for the next fiscal, which will also assist in acquisition of liabilities.
- NBFCs to outperform banks: We expect consolidation in India's financial sector to continue as efficiency and technology will play a key role in future. We expect NBFCs to report margin improvement in FY24F, while banks to face margin compression and expect NBFCs to outperform banks during the year. We prefer either lenders with superior growth outlook and premium return ratios like HDFC Bank, Bajaj Finance, or else lenders providing attractive risk-reward like SBI, MMFS & Spandana Spoorthy.

Capital Goods

- Healthy revenue-led growth: Capital goods companies under our coverage universe reported healthy execution in 4QFY23 with a revenue growth of 13.4% YoY (23.5% ex-L&T). All companies reported double-digit YoY revenue growth in the range of 10% to 29%, with strong revenue growth seen in Cummins India (29%), KEC International (29.2%), Siemens (28.8%), and ABB (22.5%). The EBITDA margin of our capital goods coverage universe declined by 47bp YoY due to lower margins in L&T, KEC International and Voltas. The PAT of our coverage universe increased by 16.4% YoY and 47% QoQ.
- Management commentary on the margin front: Management commentary was positive on the margin expansion front for most companies. L&T expects its margins in the project business to improve by 50bp to 9%, with 2HFY24F likely to be better than 1H. KEC International expects its EBITDA margin to improve from 4.8% in FY23 to 7% in 1HFY24F and to ~8% in 2HFY24F, as legacy projects of SAE Brazil got completed, and margin recovery in the standalone T&D segment. Voltas is likely to recover input cost escalation due to time extension by negotiating with clients, which is likely to lead to the margin recovery. Management has given guidance of 4-5% margin in FY24F-25F in projects business and 9% in the unitary cooling products segment. Thermax is likely to sustain its higher margins at 8-9% based on the current order book. ABB expects the PBT margin of 10%+ to sustain, given softening commodity prices while maintaining the overall pricing level. Cummins India went for multiple price hikes in the last 12 months. The pricing action and prudent cost management resulted in a record profit in FY23.
- Order inflow momentum sustained: Aggregate order inflow was robust, up by 36% YoY, led by a 5.8x jump in Siemens' order inflow at Rs450bn while KEC International's order inflow grew 121% to Rs68bn, L&T's order inflow grew 3% YoY, despite a high base. Thermax is the only company which reported lower order inflow on a YoY basis. New investments announced by the manufacturing sector during FY23 grew 23% YoY. We expect a new trend of private sector spending led by energy transition including renewables, electric vehicles, battery technology, and hydrogen. We expect manufacturing capex led by productivity-linked incentive or PLI schemes, supply chain diversification and China+ strategy. Industry has witnessed strong demand for data centres led by 5G/6G rollout and e-commerce growth. We expect the order inflow of our coverage universe to clock a 14% CAGR over FY2-25F.

• Maintain positive stance on the sector: We remain Overweight on the industrial sector as valuations currently factor in strong capex recovery led by various schemes like NIP, Gati Shakti, and Make in India, while the special focus on capex to provide several opportunities for companies going ahead. We reiterate our ADD rating on L&T, KEC International, Thermax, Voltas and Siemens with their order backlog providing revenue visibility along with reasonable valuations. We have a HOLD rating on ABB and Cummins India as export demand is likely to be hit in the event of a recession in the US and European countries, concerns over long-term growth of the powergen segment and rich valuations leaving limited upside from current levels.

Cement sector

- Summary of 4QFY23 results: Our analysis of India's top-15 listed cement companies shows that overall volume improvement for the industry was ~12% yoy (+17% qoq) in 4QFY23, a 4-year CAGR of ~5.5%. In our coverage, TRCL, UTCEM, JKCE and DALBHARA posted industry-leading growth, largely driven by ramp-up in their respective new capacity. On a qoq basis, the industry posted ~0.4% fall in average realization in 4Q. Total cost/t for players analyzed by us fell by ~3% qoq. On a per/t basis, avg. P&F cost was down by ~8% qoq, driven by lower benchmark prices. EBITDA/t for 15 companies analyzed by us improved by ~Rs120 qoq. The highest qoq improvement in EBITDA/t was reported by HEIM, BCORP and ORCMNT while DALBHARA posted a qoq decline. We saw profitability recovering in 2HFY23 from a multi-year low in 1HFY23, driven by lower P&F cost and the benefit of operating leverage. We feel there will be substantial improvement in 2HFY24F.
- Management commentary: On demand, management commentary from most companies indicated that cement demand (growth of 7-8% in FY24F) in the medium term is encouraging in view of the promising factors like a good monsoon, strong infrastructure spending and supported by the housing sector on higher pre-election spending. On pricing, management commentary highlighted stable prices so far in 1QFY23, given the focus on volume, and there are indications that a price hike is only post monsoon. On costs, in the medium term, a sharp drop in global fuel prices (pet-coke/coal prices are down >60% from their peak) over the last two-three months should lead to a fall in fuel cost for most players in 1HFY24F (unless there is some high-cost inventory; a few companies highlighted that major benefits of fuel cost decline will come from 2QFY24F) which, in turn, will improve the margin profile of the industry if the trend sustains.
- Unit EBITDA: We expect a material reduction in 1HFY24F as most companies indicated (likely from 2QFY24F) another ~15-20% drop in P&F cost in the next few quarters. Recently, with a higher correction in global pet-coke and coal prices (~17-26% from Mar 2023 exit levels), we feel the industry could improve EBITDA/t by Rs200-250 in FY24F.
- **Pricing**: Our channel checks suggest that pan-India average cement prices remained flat mom in May 2023 while cement prices declined ~1.5% mom in the East and South, while marginally improving in the northern, western and central regions. Historical data analysis reveals that pre-election years are not great for prices. Price hikes were attempted by producers in 4Q and even in Apr-May 2023, but they didn't sustain. We stay cautious on the pricing front.
- **Preferred picks**: With the benefit of low-cost fuel and better demand conditions, we believe the margins will continue to improve in FY24F, despite muted cement prices. We retain our Overweight stance on the sector with UTCEM, DALBHARA and BCORP as our top stock picks.
- Our 4QFY23 review note: <u>https://tinyurl.com/4nejwbr6</u>

Chemicals sector

 Chemical players were disappointed in 4QFY23 as revenue was under pressure due to subdued demand, Near-term demand concerns persist for specialty chemical players with higher exposure to exports/discretionary segments, given the talk of a global economic slowdown. Please note that most Indian chemical companies can report higher gross margin, but PAT will be destroyed by falling volume. We have seen this in the case of Atul and amine-makers last quarter.

- HFC-125: Volume is dipping as the US gears up to stringent emission norms from CY24.
 - The US is going to reduce the HFC emission quota from Jan 2024 by 93mt of CO2 equivalent. Hence, the demand for the highest GWP (global warming potential) product, i.e., HFC-125 (R-125) was supposed to decline. The same has started happening now. CO2 equivalent is a direct measure of GWP. An HFC with a higher CO2 equivalent will have a higher GWP; hence, its usage will decline when the quota comes into force. Please note that HFC-125 has the highest GWP (1 Kg= 6t CO2 equivalent to around 6x of R-32). HFC-125 had been the mainstay for Gujarat Fluorochemicals or GFL's and SRF's profits in the past few quarters and hence, volume decline doesn't bode well for the profits in the coming quarters. Sell GFL and SRF.
- Camlin Fine Sciences has an advantage over Clean Science and Technology in the MEHQ market.
 - The global market for MEHQ is around 13,000t and is growing at the rate of 1-2%. Primarily. MEHQ is used in SAP (super absorbent polymer), which is used in diapers. Clean Science and Technology alone has ~7,000t capacity; another 2,500t is with Camlin Fine Sciences. Vinati Organics is also entering this market, but it is likely to be less competitive than Clean Science and Technology or Camlin Fine Sciences. Camlin Fine Sciences' diphenol plant had not stabilized. Hence, it was not at all competitive with Clean Science and Technology in MEHQ and BHA. However, as its diphenol plant has now stabilized, which is shown by rising exports of HQ (earlier, its India business was importing HQ) Camlin Fine Sciences has turned competitive in the MEHQ market and is consistently cutting prices. The cost of production of MEHQ for Camlin Fine Sciences is at least Rs150/ kg lower than in the case of Clean Science and Technology, if it uses captive HQ and doesn't need to take the losses of catechol. Hence, it's likely that Camlin Fine Sciences will cut the prices of MEHQ to as low as 550-600/kg, and Clean Science and Technology will have to follow suit. The pricing trend in May 2023 indicates the same as Camlin Fine Sciences has reduced its prices. For Camlin Fine Sciences, we have valued its stock at 20x FY24F EPS to arrive at our higher target price of Rs300.
- Market is betting that Anupam Rasayan will be the next PI Industries
 - Flupyroxystrobin is the new insecticide by Syngenta which was in the R&D stage till 2022. Anupam Rasayan (as well as other Indian companies) appears to have got the contract to manufacture flupyroxystrobin for Syngenta. However, please note that till now, sales of Flupyroxystrobin are 0. While it can become like what pyroxasulfone became for PI Industries, please note that it took 10 years for pyroxasulfone to achieve US\$250m in sales. Moreover, insecticides like flupyroxystrobin are facing serious headwinds from gene-edited seeds. The market appears to be desperately looking for its second PI Industries, but that rarely happens. Please note many names that were touted as a second BHEL or L&T in the 2005-07 bull market don't exist anymore! We had a painful experience with Suzlon, BHEL, Lanco, etc. when after putting a SELL these stocks doubled and later plunged 99%, 80%, and 100%, respectively. So, stock prices can still go up, but risk management needs that one should steer clear of names like Anupam Rasayan, Astec LifeSciences, Ami Organics, etc.

Consumer staples sector

 Our FMCG coverage universe delivered an 11.1% yoy sales growth in 4QFY23. Urban markets grew ahead of rural markets. Rural markets have likely bottomed out and are expected to gradually recover while urban markets are expected to continue their growth momentum. We expect the pricing growth to taper off at a faster pace while volume growth recovery will be gradual.

- Our paints coverage universe reported a sales growth of 10.8% yoy in 4QFY23 with decorative paint volume growing in the range of 12-16% yoy. Demand conditions remained stable during the quarter, with broad-based growth across cities and towns. Adjacent segments like waterproofing and construction chemicals continued to grow at a faster pace while exterior paints were impacted due to the monsoons. Distribution expansion continued at an accelerated pace in FY23, with a similar aggression expected in FY24F. Asian Paints' management believes that the unorganized segment's contribution is expected to inch back to 30% (given normalized supply chains) which had fallen to 25%. Paint companies sounded sanguine on near-term demand with expectations of a double-digit volume growth continuing in 1QFY24F as well.
- Our FMCG pack reported EBITDA growth of 14% with EBITDA margin expansion of 55bp yoy (-22bp qoq) in 4QFY23. With overall inflation easing sequentially, we expect the companies under our coverage to step up adspends and pass on some pricing benefits to consumers, thereby limiting sequential margin expansion. For our paints pack, with input cost inflation moderating, stable outlook on raw material prices in the near term, and complete price hikes coming through in the industrial segment, gross margin expansion on a sequential basis was strong (up 390bp/510bp gog for APNT/BRGR, respectively), resulting in a healthy EBITDA margin expansion as well (up 260/300bp gog to 21.2%/16% for APNT/BRGR, respectively). Excluding one-off, BRGR's EBITDA margin would have been 100bp higher. KNPL's margins lagged peers as gross margin expansion was limited to 150bp qoq while the EBITDA margin declined by 100bp qoq. The industrial division's EBITDA margin was still in the single digit in 4Q (vs. APNT's 11.2% PBT margin in the industrial segment). Despite healthy margin expansion and no cost headwinds coupled with normal rebating intensity, the EBITDA margin guidance remains cautious (APNT has given guidance of 18-20%, while BRGR has given guidance of 16-17% level for FY24F). KNPL's EBITDA margin outlook of low double digits (10-11%) for the industrial segment was weak, in our view, and leads us to believe that KNPL will operate at a lower EBITDA margin band for a sustained period.
- Maintain our Neutral stance on the FMCG sector with HUL (ADD, TP: Rs2,720) as our top pick. In the discretionary space, we retain our positive stance on Titan Company (ADD, TP: Rs3,150) and have a cautious outlook for paints and allied products with a REDUCE rating on APNT (TP:Rs2,820) and KNPL (TP: Rs395). We maintain our HOLD rating on BRGR (TP:Rs640) and PIDI (TP:Rs2,360).

Defence

- **Financial performance**: Defence companies' sales in 4QFY23 Hindustan Aeronautics (HAL) and Bharat Electronics (BEL) were largely in line while Bharat Dynamics or BDL's sales missed estimates. While HAL and BEL showcased strong EBITDA growth due to lower raw material expenses, BDL's performance was impacted due to supply chain problems.
- Order book: The order book for companies continues to remain strong. HAL has an order book of over Rs800bn (3x TTM sales) and a further order pipeline of Rs480bn for FY24F. Similarly, BEL has a healthy order book worth Rs607bn (3.5x TTM sales). Going ahead, BEL expects a robust order book worth more than Rs200bn in FY24F. The order backlog for BDL stands at approximately Rs240bn (~9.6x FY23 sales).
- **Guidance**: HAL has given guidance of revenue growth of 10-12% in FY24F/25F, with EBITDA margin expected to improve by 100bp yoy. BEL projects a top line growth of ~17% in FY24F and an EBITDA margin in the range of 23%-24% for the year.

- While defence companies' numbers are volatile on a quarterly basis, 4Q is usually a strong execution and order finalization quarter for these companies. Hence, a strong order pipeline, the government's focus on indigenization and export growth, in our view, bode well for defence companies.
- **Our view**: We maintain our positive stance on the defence sector. Our top stock pick is BEL. Post sharp run-up in public sector defence share prices in YTDFY24, we remain cautiously optimistic, and maintain an ADD rating on HAL and BDL.

Diagnostics

- Companies continued to slowly recover non-Covid test volume over Jan-Mar 2023. However, the double-digit revenue growth recovery is still missing. 4Q was the last quarter with a high Covid revenue base and starting 1QFY24F, the revenue growth historical comparison will be much transparent and easier to understand. Margins were largely maintained qoq.
- **Outlook**: We expect non-Covid patient volume growth to keep recovering gradually towards the double-digit yoy level, no meaningful dilution of EBITDA margin, recently acquired large labs to start delivering on higher-than-industry revenue growth combined with integration benefits from cost savings, and all acquisition debt to be repaid by Mar 2024F. We see turnaround in the sector's growth and cash flow, and incrementally turn positive on the sector.
- **Preferred stocks**: We like Dr. Lal Pathlabs over Metropolis and Thyrocare and unrated regional diagnostic labs.

Infrastructure – ports, logistics and aviation

- **Ports**: Major ports (MPs) + APSEZ cargo grew 5% yoy in Apr 2023. We expect a 7-8% yoy growth in ports' cargo in FY24F.
 - APSEZ (ADD; TP Rs823): Strong volume (up 10% yoy) and rise in EBITDA/t (mainly at Mundra) drove 4QFY23 performance. Ex-acquisitions, we expect a 12% EBITDA CAGR (FY20-24F). Our target price implies 11.6x FY25F EV/EBITDA (10% discount to 5-year avg.).
 - GPPV (ADD; TP Rs148): Strong container volume and tariff offset weak bulk cargo in 4QFY23. Connectivity to the Dedicated Freight Corridor or DFC may boost GPPV in FY24F, while JNPT could be connected to the DFC in 1.5-2 years. We forecast an 18% EBITDA CAGR (FY23-25F). We feel that at CMP, GPPV is factoring in (a) a tepid volume growth, and (b) no concession extension post FY29F.
- **Logistics**: In Apr 2023, rail export-import (EXIM) container cargo rose by 13.4% yoy (vs. 9% yoy growth in 4QFY23).
 - Concor (ADD; TP Rs940): In 4QFY23, despite a 5% yoy dip in originating cargo, and EBITDA rose by 13% yoy. We expect a sharp volume growth for Concor over FY23-25F, driven by the shift in cargo from road to rail after the start of the DFC.
 - BlueDart Express (HOLD; TP Rs6,250): In 4QFY23, weak volume growth and margin led to a 13% qoq EBITDA decline. This was the fourth consecutive quarter of margin decline, but the silver lining is that the pace of qoq decline abated from 351bp in 1Q to 68bp in 4Q. We expect BDE's EBITDA margin to decline to 16.7% due to intense competition in the air cargo business (like in 3-4QFY23). We value BDE at 14x EV/EBITDA FY25F.
 - VRL Logistics (REDUCE; TP Rs426): In 4QFY23, EBITDA margin (16.3%) dipped 172bp yoy due to a 348 bp yoy fall in GT EBITDA margin. We expect VRL Logistics' GT segment's EBITDA margin to fall from 16.4% in FY23 to 14% in FY25F due to commissioning of the DFC in FY24F-25F. We factor in a 7% GT volume CAGR (FY23-25F). We value VRL at 10x EV/EBITDA FY25F.
 - Delhivery (REDUCE; TP Rs268): 4QFY23 saw dwindling growth for the second consecutive quarter as the losses kept mounting. We have

concerns about Delhivery's profitability as a tariff hike in the near term is unlikely, capping the operating leverage. We feel the losses may continue for the next two years.

- Aviation: Traffic in Apr 2023 we did not compare with Apr 2020 as the Covid-19 pandemic started in Mar 2020, but we compared with daily Feb 2023 numbers: Daily total revenue passenger km (RPK: domestic + international for Indian carriers ex-Alliance Air) was 3.7% lower than in Feb 2023 (which was 5% above Feb 2020). Industry passenger load factor (PLF: 84.8%) is like the average of Apr 2018 and Apr 2019 (85.8%). Despite its aircraft on ground from Oct 2022, industry's daily ASK rose by 13% over Sep 2022 to Apr 2023.
 - IndiGo (REDUCE; TP Rs1,600): The super-normal profit in 3Q petered out in 4QFY23. IndiGo's adj. PAT declined by 62% qoq. We factor in a yearly growth of 13% in ASK and RPK over FY23-25F. We consider a decline in tariff in FY24F because of higher tariff in 3QFY23 due to industry capacity constraints (unlikely to sustain). We value the business at 9.5x FY25F EV/EBITDAR.
- Infrastructure: Average order book or OB-to-sales is healthy at ~2.8x and companies in our coverage reported steady EPC sales growth in 4QFY23. The companies in our coverage universe must fund 21% of their latest OB (like in Mar 2019). Most of the stocks in our coverage trade at fair valuations and we believe the near-term upside is limited.

Information technology sector

- 4QFY23 earnings summary: 4QFY23 revenue performance of companies under our coverage was impacted by moderation in the financial services (FSI) vertical, persistent weakness in retail & hi-tech verticals, and ramp-down as well as delayed ramp-up of projects. This, coupled with macroeconomic uncertainty, led to a wide revenue guidance range (4%-7% in constant currency or CC terms in FY24F) by Infosys, qoq revenue decline guidance by Wipro (-3% to -1%) and 6%-8% CC growth guidance by HCL Technologies, despite a relatively better 4Q, BFSI vertical outlook, and healthy yoy new deal wins & pipeline commentary. Across Tier-2 companies, Persistent Systems (PSYS), Coforge, L&T Technology Services (LTTS) and Cyient's performances were better, but soft in the case of LTIMindtree and weak for Mphasis. Incremental moderation in FSI spending remains a key downside risk to our FY24F estimates while the conclusion of delayed deals in Europe and better ramp-up in the existing book could surprise positively.
- YoY growth of LTM order book moderates with low roll-off visibility: Barring Wipro, last 12-month or LTM deal win growth moderated across Tier-1 companies. TCV was down 36.4% qoq and 8.7% yoy for Infosys (BFSI large deal count at 4 vs. 6 in 3Q), new deal wins total contract value or TCV declined 25.5% qoq and 41.4% yoy for Tech Mahindra, TCS' BFSI deal wins declined by 6% qoq, adjusting for a mega deal, while HCL Technologies' new deal wins TCV fell for the second consecutive quarter. LTM order book growth moderated across Tier-2 companies, barring LTIMindtree. Management commentaries suggest that although the deal velocity has accelerated (especially in Europe) select discretionary projects could be cancelled if the sentiment deteriorates further while the rising mix of vendor consolidation and cost take-out deals could exert pressure on margins, in our view.
- Margins could remain volatile in the near term: EBIT margin performance was aided by improving billability of freshers, easing attrition, and moderation in sub-contractor expenses while the impact from project ramp-down, higher onsite wage cost and company-specific one-offs were key offsets. Wage hike could be a key headwind in 1HFY24F, and despite that the quantum could significantly be lower than in the previous years. Although moderating sub-contractor and backfilling cost, improving deployability of freshers and right-sizing of employee pyramid are key margin tailwinds, complex deal structuring and upfront investments to support large deals are key headwinds which could limit the FY24F EBIT margin expansion thesis.

• We remain selective as performance divergence is broadening: We continue to be selective and prefer structural stories, given that performance divergence across our coverage universe is broadening. Though the shift in the CY23F IT spending landscape, from growth to cost take-out, favours the scale of operations of Tier-I companies in a market with rising competitive intensity, recent earnings performance suggest that select Tier-II companies continue to defend their wallet share better. Finally, though we would have liked better entry points for our Tier-II coverage universe given the average entry P/E multiple (24.6/21x FY24F/25F consensus EPS) is still higher than that of Tier-I companies at 19x/16.9x for FY24F/25F, respectively, we highlight that broadening performance divergence in the backdrop of waning sectoral tailwinds of CY20/21 suggest that select Tier-II names may continue to attract a scarcity premium

Metals & mining sector

- The supply chain-filling rally in steel is over, as are the xl sheet-based dreams of debt-free steel companies. In most cases, deleveraging was artificial as big companies had delayed payments to small vendors, and, in turn, those vendors got those invoices discounted on the SIDBI trade discount window. It was also indeed magical that steel companies had customer advances amounting to US\$800m (Tata Steel in FY21) in their balance sheets. All these led to massive artificial deleveraging, and the same is reversing.
- Please note that steel spreads still need to collapse, and if the world is slowing and Chinese exports are rising fast, then it's a matter of time before we will have at least -1SD spreads over raw material. In that scenario, most Indian steel stocks (barring JSW Steel – which is beyond our comprehension) will start trading near 0.5x book value. That's the time to buy steel stocks, not now.
- We remain sellers in steel names. You will hear a plenty of noise in the coming months of a) China cutting steel production (it never does- unless demand has collapsed there), b) Chinese exports coming down (it has never happened at a sustained level), and c) there is never a first time vis-à-vis China. So, investing based on Chinese announcements or promises, is fraught with risk. Use the bounce, if any, to come out of steel names. In metals, keep Hindalco.

Oil and Gas

- A significant slowdown in Europe and continued softness in China led to low gas prices in Europe, it's not a supply issue but just a demand decline playing havoc with our call on strong LNG prices. Till now, we have gone wrong on our strong LNG thesis. However, some sectors will gain in the current scenario – it's the evergreen pharma sector. The chemical sector will face headwinds by way of demand decline and hence, while spreads may rise, the top-line decline will lead to a fall in earnings. However, generic API-makers will enjoy benefits at both ends - lower raw material costs and bottoming-out API prices.
- European gas storage is nearing its all-time high as imported gas consumption in Europe is declining by approximately 20% YoY every week. This is leading to a fall in power, gas, and base chemical prices. Please note that most Indian chemical companies can report higher gross margin, but PAT will be destroyed by falling volume. We have seen this in the case of Atul and aminemakers last quarter. B2B businesses like Clean Science and Technology, etc. will take a hit in the coming quarters. On the other hand, API-makers will benefit as costs can decline by 5-10%. Various companies in their commentaries have indicated that price erosion is bottoming out. In fact, there are a few hints of rising API prices as well.
- CGD firms; growth is reliant on domestic output, and the lower APM is unlikely to be of significant assistance
 - Given crude oil prices of US\$80/bbl, a 12.67% slope long-term contract is not feasible for Indian CGD and PNG players, necessitating their dependence on domestic APM natural gas. Limited to an increase of 4-4.5bcm in the next three to four years, the growth of Indian natural gas

output will limit CGD volume growth to a 10% CAGR over FY23F-26F. Achieving the government's aim of 100% indigenous urea production by 2025F hinges on international urea and LNG prices. If urea prices remain subdued, it may not be profitable to import costly LNG and produce urea from it. Although CNG stations are expected to double over the next three years and PNG connections to increase by 50%, a decline in CNG sales per station by 25% to 2mmscm from 2.7mmscm/station/annum (FY23 sales) is anticipated due to the above reasons. We remain cautious on Indian CGD companies.

Pharma

- US generics recovery limited to a few players: Against general optimism on US pricing dynamics (portfolio rationalization by larger players/competitor exits), commentary from most managements has broadly remained unchanged (cautious) with price erosion guided to remain in high single digits. We believe there have been very specific beneficiaries (Aurobindo, Zydus) and a broad-based recovery is still elusive. gRevlimid continues to be one the key near-term drivers in the US market for most companies and is likely to continue the momentum with a higher volume share in FY24F. SUNP expects its specialty portfolio to scale up steadily, although generics revenue is likely to be hit due to Halol import alert and Mohali regulatory issues. Zydus (35+ launches including transdermals, gVascepa and a couple of REMS products) and Aurobindo (double-digit growth in Eugia, pick-up in oral solid sales in 1HFY24F and gRevlimid launch in Oct 2023F) sounded the most bullish in the near term.
- Domestic growth was healthy, price hikes/productivity improvement to drive FY24F growth: India growth was relatively stronger, with most companies reporting between 10-12% YoY growth (ex-Covid). NLEM revisions in Jan 2023 impacted 4Q to some extent but will be mitigated with price hikes that started in Apr 2023. Almost all companies added field force, either to expand their geographical coverage or to ensure better product focus with the creation of new divisions. Some companies also expanded their sales force in the consumer health business (Cipla, Torrent Pharma). FY24F domestic growth should be strong led by higher-than-normal price hikes and productivity improvement from the recently added field force.
- One of the worst quarters for margins in recent times: 4QFY23 was probably one of the worst quarters in recent history, in terms of margins, as companies suffered from higher channel inventory at the client's end, higher raw material inflation, higher freight cost and negative operating leverage. Ajanta Pharma, Gland Pharma, Alkem, Dr. Reddy's Labs, Laurus Labs, IPCA and Divis Labs sharply missed consensus margin expectations (by 10-20%). 4Q probably marked the trough for margins with improvement likely from softening raw material prices, reduction in freight cost and receding inventory levels. Additionally, productivity improvement from the recently added field force should help. SUNP alluded to a sharp increase in R&D spending, which should limit the margin expansion. With a likely recovery in revenue in 2HFY24F, CDMO players (Divis, Laurus, Gland) are likely to post a recovery in margins.

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

India Strategy Note | June 07, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.